|
rs1447295
|
|
|
0.800 |
GeneticVariation |
BEFREE |
• The frequencies of three CaP risk alleles (rs1447295 [8q24], P= 0.004; rs1571801 [9q33.2], P= 0.03; rs11228565 [11q13], P= 0.02) were significantly higher in men with 'unfavourable' pathological characteristics.
|
22077888 |
2012 |
|
rs1052133
|
|
|
0.070 |
GeneticVariation |
BEFREE |
XPD Asp312Asn polymorphism is associated with PCa risk in Asians and hOGG1 Ser326Cys polymorphism is associated with PCa risk in Caucasians and Asians.
|
22890093 |
2012 |
|
rs1799793
|
|
|
0.070 |
GeneticVariation |
BEFREE |
XPD Asp312Asn polymorphism is associated with PCa risk in Asians and hOGG1 Ser326Cys polymorphism is associated with PCa risk in Caucasians and Asians.
|
22890093 |
2012 |
|
rs486907
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Xenotropic murine leukemia virus (MLV)-related virus (XMRV) was initially identified in prostate cancer (PCa) tissue, particularly in the prostatic stromal fibroblasts, of patients homozygous for the RNASEL R462Q mutation.
|
21447170 |
2011 |
|
rs2301241
|
|
|
0.010 |
GeneticVariation |
BEFREE |
With respect to acrylamide-gene interactions, only rs1800566 in NAD(P)H quinone dehydrogenase 1 (NQO1) and rs2301241 in thioredoxin (TXN) showed a nominally statistically significant multiplicative interaction with acrylamide intake for advanced prostate cancer risk.
|
29697282 |
2019 |
|
rs1800566
|
|
|
0.020 |
GeneticVariation |
BEFREE |
With respect to acrylamide-gene interactions, only rs1800566 in NAD(P)H quinone dehydrogenase 1 (NQO1) and rs2301241 in thioredoxin (TXN) showed a nominally statistically significant multiplicative interaction with acrylamide intake for advanced prostate cancer risk.
|
29697282 |
2019 |
|
rs7965399
|
|
|
0.030 |
GeneticVariation |
BEFREE |
While this association was not identified in men from the general population, one IGF-1 SNP rs7965399 was associated with higher mean Bodily Pain scale scores in men from the general population that was not found in men with prostate cancer.
|
25724697 |
2015 |
|
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While there was a trend toward an earlier age at diagnosis, overall the clinicopathologic features of PCa were not significantly different in G84E carriers and non-carriers.
|
29181843 |
2018 |
|
rs1221877686
|
|
|
0.010 |
GeneticVariation |
BEFREE |
While there was a trend toward an earlier age at diagnosis, overall the clinicopathologic features of PCa were not significantly different in G84E carriers and non-carriers.
|
29181843 |
2018 |
|
rs138213197
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While the HOXB13 G84E mutation may be rare, there may be a future role in genetic testing for this mutation after further studies of clinical utility in assessing prostate cancer risk.
|
24310616 |
2014 |
|
rs6434568
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we evaluated these two tSNPs together based on the risk alleles (that is, rs6434568 C and rs16834898 A), we found that the combined genotypes with four risk alleles were associated with an increased risk of PCa compared with those carrying 0-3 risk alleles (1.53, 1.19-1.97), and this increased risk was more pronounced among subjects of≤70 years (1.80, 1.24-2.62), Gleason score≥7 (1.68, 1.28-2.22) and PSA level≥20 (1.64, 1.24-2.18).
|
23459097 |
2013 |
|
rs16834898
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we evaluated these two tSNPs together based on the risk alleles (that is, rs6434568 C and rs16834898 A), we found that the combined genotypes with four risk alleles were associated with an increased risk of PCa compared with those carrying 0-3 risk alleles (1.53, 1.19-1.97), and this increased risk was more pronounced among subjects of≤70 years (1.80, 1.24-2.62), Gleason score≥7 (1.68, 1.28-2.22) and PSA level≥20 (1.64, 1.24-2.18).
|
23459097 |
2013 |
|
rs4588
|
|
|
0.020 |
GeneticVariation |
BEFREE |
When studies were stratified by cancer type, our results indicated that rs4588 significantly increased the risk of breast cancer and digestive system tumor, but not in prostate cancer and non-small cell lung cancer, while rs7041 significantly increased the risk of non-small cell lung cancer.
|
31467173 |
2019 |
|
rs1256049
|
|
|
0.030 |
GeneticVariation |
BEFREE |
When patients were grouped according to smoking status, the ESR2 rs1256049 AA genotype (OR = 0.48, 95 % CI 0.25-0.95, P < 0.05) and ESR2 rs4986938 AG + AA genotype (OR = 0.64, 95 % CI 0.41-1.00, P < 0.05) showed significantly decreased PCa risk in the ever-smoker group.
|
26251204 |
2015 |
|
rs7254617
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When estimated these two SNPs together, the combined genotypes with 2-4 risk alleles (rs2295080 T and rs7254617 A alleles) were associated with an increased risk of PCa compared with 0-1 risk alleles, which was more pronounced among subgroups of age >71 years, smokers, drinkers and no family history of cancer.
|
22815832 |
2012 |
|
rs2295080
|
|
|
0.020 |
GeneticVariation |
BEFREE |
When estimated these two SNPs together, the combined genotypes with 2-4 risk alleles (rs2295080 T and rs7254617 A alleles) were associated with an increased risk of PCa compared with 0-1 risk alleles, which was more pronounced among subgroups of age >71 years, smokers, drinkers and no family history of cancer.
|
22815832 |
2012 |
|
rs3736001
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When considering clinical factors, rs3736001, which is a nonsynonymous cDNA single nucleotide polymorphism (Glu39Lys), showed an association with prostate specific antigen 10 ng/ml or greater and prostate cancer risk.
|
21497359 |
2011 |
|
rs2735839
|
|
|
0.800 |
GeneticVariation |
BEFREE |
When comparing prostate cancer cases with low PSA controls, alleles at genetic markers rs1512268, rs445114, rs10788160, rs11199874, rs17632542, rs266849, and rs2735839 were associated with an increased risk of prostate cancer, but the effect-estimates were attenuated to the null when using high PSA controls (Pheterogeneity in effect-estimates < 0.04).
|
24753544 |
2014 |
|
rs17632542
|
|
T |
0.750 |
GeneticVariation |
GWASCAT |
When comparing prostate cancer cases with low PSA controls, alleles at genetic markers rs1512268, rs445114, rs10788160, rs11199874, rs17632542, rs266849, and rs2735839 were associated with an increased risk of prostate cancer, but the effect-estimates were attenuated to the null when using high PSA controls (Pheterogeneity in effect-estimates < 0.04).
|
24753544 |
2014 |
|
rs20417
|
|
|
0.040 |
GeneticVariation |
BEFREE |
When all groups were pooled, we did not detect a significant association of rs20417 polymorphism with prostate cancer risk.
|
22782583 |
2012 |
|
rs2236225
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When all groups were pooled, there was no evidence that G1958A had significant association with PCa under additive, recessive, dominant, and allelic models.
|
24197977 |
2014 |
|
rs8176704
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We used three single nucleotide polymorphisms (SNPs) (rs8176746, rs505922, and rs8176704) to determine ABO genotype in 2,774 aggressive prostate cancer cases and 4,443 controls from the Breast and Prostate Cancer Cohort Consortium (BPC3).
|
26268879 |
2015 |
|
rs505922
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We used three single nucleotide polymorphisms (SNPs) (rs8176746, rs505922, and rs8176704) to determine ABO genotype in 2,774 aggressive prostate cancer cases and 4,443 controls from the Breast and Prostate Cancer Cohort Consortium (BPC3).
|
26268879 |
2015 |
|
rs887391
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We then genotyped these two SNPs in the remaining cases (n=2,393) and controls (n=1,222) from CAPS and found that rs887391 at 19q13 was highly associated with PCa risk (P=9.4 x 10(-4)).
|
19318570 |
2009 |
|
rs4680
|
|
|
0.090 |
GeneticVariation |
BEFREE |
We suggest that bladder cancer but not prostate cancer and kidney cancer could be significantly associated with the Val158Met polymorphism.
|
27055785 |
2016 |